Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00JRA
|
|||
| Former ID |
DCL000703
|
|||
| Drug Name |
Asenapine
|
|||
| Synonyms |
Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1], [2] | |
| Company |
Organon BioSciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16ClNO
|
|||
| Canonical SMILES |
CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
|
|||
| InChI |
1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
|
|||
| InChIKey |
VSWBSWWIRNCQIJ-GJZGRUSLSA-N
|
|||
| CAS Number |
CAS 65576-45-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10255109, 14848952, 46237632, 47510131, 47805605, 79842828, 85093880, 99299533, 103603974, 104179044, 113451024, 126659506, 126685375, 135119080, 135650779, 136368088, 137272164, 140825715, 144115631, 152057475, 152343981, 160646093, 164835962, 175269541, 176484918, 223677959, 224309689, 226973261, 245261846, 251971432, 252447779
|
|||
| ChEBI ID |
CHEBI:71246
|
|||
| ADReCS Drug ID | BADD_D00172 ; BADD_D00173 | |||
| SuperDrug ATC ID |
J04AD02
|
|||
| SuperDrug CAS ID |
cas=000910861
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Asenapine maleate (adjusted p-values: 6.52E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Asenapine maleate (adjusted p-values: 3.66E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Asenapine maleate (adjusted p-values: 3.50E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hyaluronidase (HYAL) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 22). | |||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.